Guo et al. (2017) conducted a phase I clinical trial to evaluate the efficacy of EGFR-specific CAR-T cells in patients with relapsed/refractory stage 4 biliary tract cancers. The gene discussed is EGFR; the disease is biliary tract neoplasm.